ProQR Therapeutics N.V. (PRQR) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
ProQR Therapeutics N.V. (PRQR) Bundle
Looking to assess the intrinsic value of ProQR Therapeutics N.V.? Our PRQR DCF Calculator integrates real-world data with extensive customization options, allowing you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0 | .0 | 1.4 | 4.2 | 6.8 | 7.8 | 9.0 | 10.4 | 12.0 | 13.9 |
| Revenue Growth, % | 0 | -100 | 0 | 198.15 | 61.36 | 15.34 | 15.34 | 15.34 | 15.34 | 15.34 |
| EBITDA | -181.7 | -142.3 | -57.3 | -58.9 | -25.1 | -4.7 | -5.4 | -6.3 | -7.2 | -8.3 |
| EBITDA, % | -9015.42 | 100 | -4058.2 | -1398.56 | -369.93 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 2.1 | 2.3 | 2.5 | 2.6 | 2.6 | 6.3 | 7.2 | 8.3 | 9.6 | 11.1 |
| Depreciation, % | 105.85 | 100 | 178.87 | 61.32 | 38.58 | 79.98 | 79.98 | 79.98 | 79.98 | 79.98 |
| EBIT | -183.8 | -144.6 | -59.8 | -61.4 | -27.7 | -4.7 | -5.4 | -6.3 | -7.2 | -8.3 |
| EBIT, % | -9121.27 | 100 | -4237.07 | -1459.89 | -408.5 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 116.7 | 79.1 | 195.5 | 98.8 | 124.0 | 7.8 | 9.0 | 10.4 | 12.0 | 13.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .4 | .0 | 59.7 | 1.3 | 3.4 | 4.0 | 4.6 | 5.3 | 6.1 |
| Account Receivables, % | 0 | 100 | 0 | 1417.79 | 19.47 | 43.89 | 43.89 | 43.89 | 43.89 | 43.89 |
| Inventories | .4 | .4 | .3 | .0 | .0 | 2.2 | 2.5 | 2.9 | 3.3 | 3.8 |
| Inventories, % | 17.59 | 100 | 19.68 | 0.17005 | 0 | 27.49 | 27.49 | 27.49 | 27.49 | 27.49 |
| Accounts Payable | .5 | .2 | .2 | .4 | 1.6 | 2.7 | 3.1 | 3.6 | 4.1 | 4.7 |
| Accounts Payable, % | 23.02 | 100 | 14.11 | 9.71 | 23.66 | 34.1 | 34.1 | 34.1 | 34.1 | 34.1 |
| Capital Expenditure | -.6 | -1.0 | -.5 | -.7 | -1.4 | -1.6 | -1.9 | -2.2 | -2.5 | -2.9 |
| Capital Expenditure, % | -30.01 | 100 | -35.75 | -17.54 | -21.05 | -20.87 | -20.87 | -20.87 | -20.87 | -20.87 |
| Tax Rate, % | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 |
| EBITAT | -184.2 | -145.0 | -59.9 | -61.5 | -28.0 | -4.7 | -5.4 | -6.3 | -7.2 | -8.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -182.6 | -144.4 | -57.4 | -118.9 | 32.7 | -3.3 | -.5 | -.6 | -.7 | -.8 |
| WACC, % | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -22 | |||||||||
| Present Terminal Value | -17 | |||||||||
| Enterprise Value | -22 | |||||||||
| Net Debt | -103 | |||||||||
| Equity Value | 81 | |||||||||
| Diluted Shares Outstanding, MM | 81 | |||||||||
| Equity Value Per Share | 1.00 |
What You Will Get
- Editable Forecast Inputs: Easily adjust assumptions (growth %, margins, WACC) to develop various scenarios.
- Real-World Data: ProQR Therapeutics N.V. (PRQR) financial data pre-loaded to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that can be tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing efficiency.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for ProQR Therapeutics N.V. (PRQR).
- Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
- User-Friendly Dashboard: Clear and informative charts and summaries to help you interpret your valuation findings.
- Designed for All Levels: An accessible, intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- 1. Download the Template: Obtain and open the Excel file containing ProQR Therapeutics N.V. (PRQR) preloaded data.
- 2. Adjust Key Assumptions: Modify essential inputs such as growth projections, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand diverse valuation results.
- 5. Present with Assurance: Deliver professional valuation analyses to reinforce your decision-making.
Why Choose This Calculator for ProQR Therapeutics N.V. (PRQR)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your specific analysis needs.
- Real-Time Feedback: Observe immediate updates to ProQR’s valuation as you change inputs.
- Preloaded Data: Comes with ProQR’s latest financial information for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for strategic decision-making.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for assessing ProQR Therapeutics (PRQR) investments.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights for clients considering ProQR Therapeutics (PRQR) stock.
- Students and Educators: Utilize real-world biotechnology data to learn and teach financial modeling techniques.
- Healthcare Enthusiasts: Gain insights into how biotech companies like ProQR Therapeutics (PRQR) are valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled ProQR Therapeutics N.V. (PRQR) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for ProQR Therapeutics N.V. (PRQR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.